Rubius Therapeutics to Announce Third Quarter 2019 Financial Results
05 nov. 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences
17 oct. 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference
03 sept. 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
13 août 2019 08h00 HE
|
Rubius Therapeutics
On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc....
Rubius Therapeutics to Announce Second Quarter 2019 Financial Results
07 août 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
25 juil. 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
05 juin 2019 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference
28 mai 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
15 mai 2019 08h00 HE
|
Rubius Therapeutics
Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019 Company Announces Transition of President Torben...
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
06 mai 2019 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...